Life Biosciences is pushing cellular rejuvenation into the clinic with ER-100, an experimental gene ...
Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma treatment VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis ...
Scientists reverse eye cell aging with ER-100 gene therapy that reprograms retinal neurons to younger states, offering hope ...
Despite groundbreaking research, many cell and gene therapies do not make it all the way to the patients. Researchers and clinicians in Lund have now presented a new model for cooperation that will ...
Gene editing could be used to treat millions of glaucoma patients. Glaucoma is a leading cause of blindness, characterized by high pressure inside the eye. Patients often rely on daily eye drops to ...
Leveraging Northway Biotech's 20+ years of CDMO expertise, Diorasis Therapeutics is advancing DT003, a single-dose AAV gene therapy for glaucoma. As part of the collaboration, Northway Biotech will ...
VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...